FilingReader Intelligence
Salubris's gene-editing drug receives China clinical trial approval
July 14, 2025 at 05:17 PM UTC•By FilingReader AI
Shenzhen Salubris Pharmaceuticals' YOLT-101 injection, a gene-editing drug for heterozygous familial hypercholesterolemia, has obtained clinical trial approval from China's National Medical Products Administration.
The drug targets PCSK9 using base editing delivered via lipid nanoparticles and was licensed from Yaotang (Shanghai) Biotechnology. Salubris holds exclusive rights for YOLT-101 in mainland China.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002294•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Shenzhen Salubris Pharmaceuticals publishes news
Free account required • Unsubscribe anytime